Figure 1.

Disease control during the first 52 weeks of treatment in all patients in the intent‐to‐treat population (A), and in patients with newly diagnosed (B) and relapsing (C) giant cell arteritis. Prespecified exploratory analysis of remission rates over time is shown. Remission was defined as absence of flare and did not include C‐reactive protein level in the definition. Patients who withdrew from the study or received escape therapy were excluded from that point. Patients with missing information on remission status were considered not in remission for that time point only. Responders (patients in remission) were analyzed; therefore, values at week 52 are slightly higher than the highest values for sustained remission, which accounts for patients not adhering to the protocol‐defined tapering regimen as nonresponders. PBO + Pred‐26 = placebo plus 26‐week prednisone taper; PBO + Pred‐52 = placebo plus 52‐week prednisone taper; TCZ‐QW + Pred‐26 = tocilizumab once weekly plus 26‐week prednisone taper; TCZ‐Q2W + Pred‐26 = tocilizumab once every 2 weeks plus 26‐week prednisone taper.